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ABSTRACT 
The NUP214-ABL1 fusion protein is a constitutively active protein tyrosine kinase that is found in 
6% of patients with T-cell acute lymphoblastic leukemia and that promotes proliferation and 
survival of T-lymphoblasts. Although NUP214-ABL1 is sensitive to ABL1 kinase inhibitors, 
development of resistance to these compounds is a major clinical problem, underlining the need 
for additional drug targets in the sparsely studied NUP214-ABL1 signaling network. In this work, 
we identify and validate the SRC family kinase LCK as a protein whose activity is absolutely 
required for the proliferation and survival of T-cell acute lymphoblastic leukemia cells that depend 
on NUP214-ABL1 activity. These findings underscore the potential of SRC kinase inhibitors and 
of the dual ABL1/SRC kinase inhibitors dasatinib and bosutinib for treating of NUP214-ABL1 
positive T-cell acute lymphoblastic leukemia. In addition, we used mass spectrometry to identify 
protein interaction partners of NUP214-ABL1. Our results strongly support that the signaling 
network of NUP214-ABL1 is distinct from that previously reported for BCR-ABL1. Moreover, we 
identify three NUP214-ABL1 interacting proteins, MAD2L1, NUP155, and SMC4, as strictly 
required for the proliferation and survival of NUP214-ABL1 positive T-cell acute lymphoblastic 
leukemia cells. In conclusion, this work identifies LCK, MAD2L1, NUP155 and SMC4 as four new 
potential drug targets in NUP214-ABL1 positive T-cell acute lymphoblastic leukemia. 
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INTRODUCTION 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T-cell progenitors 
occurring in adults and children. With current chemotherapy protocols, the outcome for pediatric 
T-ALL has improved to cure rates over 75%. However, these therapies are highly toxic. 
Moreover, adult T-ALL patients, patients with primary resistance to the chemotherapy or relapsed 
patients have an extremely poor prognosis, underscoring the need for novel therapeutic 
strategies.1,2 
 
T-ALL is a genetically heterogeneous disease that is caused by accumulation of multiple genetic 
defects in developing T-cells, affecting critical cellular processes such as cell differentiation, 
proliferation, survival and self-renewal capacity.3 Approximately 8% of T-ALL cases harbor 
fusions that involve the ABL1 tyrosine kinase gene.3 BCR-ABL1, which is the prototypical ABL1 
fusion kinase in chronic myeloid leukemia (CML) and subsets of B-cell ALL (B-ALL), is only 
sporadically found in T-ALL. In contrast, 6% of T-ALL cases express the constitutively active 
NUP214-ABL1 fusion kinase, which consists of the N-terminal region of the nuclear pore complex 
protein NUP214 and of the same C-terminal part of ABL1 as in BCR-ABL1.4 Recently, the 
NUP214-ABL1 fusion was also identified in B-ALL.5 Although NUP214-ABL1 and BCR-ABL1 are 
both constitutively active kinases that stimulate the proliferation of the leukemic cells, they differ 
from each other in almost all properties we investigated, including genetic etiology, transforming 
capacity, substrate preference and phosphorylation pattern.4,6-7 Furthermore, the kinase 
activation of NUP214-ABL1 depends on its localization at the nuclear pore complex and not on 
coiled-coil induced oligomerization and binding of the adaptor protein GRB2 like for BCR-ABL1.7 
Despite these differences, NUP214-ABL1 and BCR-ABL1 are both sensitive to ABL1 kinase 
inhibitors, and ABL1 inhibitors inhibit the proliferation of leukemic cells expressing these 
kinases,4,6,8 rendering ABL1 kinase inhibitors attractive for therapy of NUP214-ABL1 positive T-
ALL.  
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Although introduction of ABL1 kinase inhibitors was a major step forward in treatment of BCR-
ABL1 positive leukemias, it has also become clear that patients treated with these inhibitors 
sometimes relapse due to the acquisition of resistance mutations.9 These mutations are 
particularly common in BCR-ABL1 positive B-ALL and advanced CML, which, like T-ALL, are 
genetically more complex than chronic phase CML. Several mechanisms of resistance occur, 
including BCR-ABL1 mutations interfering with inhibitor binding and amplification of the BCR-
ABL1 oncogene.10 Consequently, to find therapeutics that target therapy-resistant cells, much 
effort has been invested in identifying novel proteins or pathways that are required for BCR-ABL 
mediated transformation.11 An important example is the observation that certain SRC family 
kinases are critical signaling proteins in BCR-ABL1 positive B-ALL and advanced CML.12-15 
Indeed, the SRC family kinase LYN is overexpressed in ABL1 kinase inhibitor resistant CML blast 
crisis and knockdown of LYN induces apoptosis in these cells.14 In addition, proteins interacting 
with BCR-ABL1 were recently identified,16 which may allow the identification of therapeutically 
relevant critical interactors. In contrast, unbiased studies of the NUP214-ABL1 signaling network 
are lacking and critical signaling pathways and interactors that can be therapeutically targeted 
may previously have been missed.  
 
We fear that, similar to BCR-ABL1, resistance to ABL1 inhibitors may develop readily in NUP214-
ABL1 positive T-ALL. Although clinical experience with ABL1 inhibitors in NUP214-ABL1 positive 
T-ALL is limited, a recent report on a NUP214-ABL1 positive patient for which imatinib was added 
to his therapeutic scheme indeed showed that the patient, after obtaining a rapid remission, 
fatally relapsed.17 In this study, we aimed to identify novel therapeutic targets in NUP214-ABL1 
positive T-ALL by using two approaches. First, we investigated the therapeutic potential of SRC 
family kinases. In addition, we performed an unbiased mass spectrometry and siRNA based 
screen to identify proteins that are critical for the survival and proliferation of NUP214-ABL1 
positive T-ALL cells. 
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METHODS 
Constructs 
Hemagglutinin (HA) tagged NUP155 and SMC4 cDNA were synthesized (Genscript) and cloned 
into the XhoI and EcoRI restriction sites of pMSCV-puro (Clontech). NUP214-ABL1 and BCR-
ABL1 constructs were described previously.7  
 
Cell culture 
ALL-SIL, K-562, KE-37, RPMI-8402, JURKAT, SUP-T1, RLD-1 and L-5178-Y (DSMZ) were 
cultured in RPMI-1640 medium with 20% fetal calf serum (FCS). NA10073 and NA10075 cell 
lines were established from mouse T-ALL leukemias induced in a NUP214-ABL1 bone marrow 
transplant assay7 and were cultured in RPMI-1640 with 20% FCS. HEK293T cells (DSMZ) were 
cultured in RPMI-1640 with 10% FCS. Transfections were performed using Turbofect reagent 
(Fermentas). 
 
Immunoblotting 
Samples were processed according to standard procedures using the following antibodies: anti-
FYN (Fyn3), anti-LCK (3A5), anti-ABL1 (24-11) and anti-ERK2 (Santa Cruz Biotechnology); anti-
NUP155 (ab73292) (Abcam); anti-phospho-SRC family (Tyr416), anti-phospho-ABL1 (Tyr245), 
anti-SMC4 (D14E2) and anti-MAD2L1 (D8A7) (Cell Signaling); anti-HA tag (12CA5) (Roche) and 
peroxidase-labeled anti-mouse/anti-rabbit antibodies (Amersham).  
 
siRNA knockdown  
Human T-ALL cell lines were electroporated on a Genepulser Xcell instrument (Biorad) with 
400nM siRNA. For mouse T-ALL cell lines, two electroporations were performed with a 24 hour 
interval. Viable cell numbers and viability were determined on a Vi-cell XR cell viability analyzer 
(Beckman Coulter) or on a Guava easyCyte HT (Millipore). Knock-down efficiencies were 
evaluated by immunoblotting or by quantitative reverse transcriptase PCR (qRT-PCR). siRNA 
sequences are in Supplementary table 1. 
 
 7
Quantitative reverse transcription PCR  (qRT-PCR)  
qRT-PCR reactions were performed on a LightCycler 480 instrument (Roche). Relative 
expression levels were calculated according to the ΔΔCt method using GAPDH, UBC or HPRT as 
normalizer genes.  
 
Drug sensitivity  
For dose-response curves, 5 x 105 cells were seeded in 1 mL of growth medium and incubated in 
the presence of PP2 (Calbiochem) for 48 hours. Cell proliferation was determined using CellTiter 
96 AQueous One reagent (Promega). Apoptosis analysis was performed using the PE Annexin V 
apoptosis detection kit I (BD Biosciences). Flow cytometry was performed on a FACSCanto (BD 
Biosciences). 
 
Mass spectrometric analysis of NUP214-ABL1 protein complexes  
Biological duplicates of the pull-down experiments and mass spectrometric analyses were 
described previously.16 
 
(Co-)Immunoprecipitation 
Cells were lysed on ice for 30 minutes in cell lysis buffer (Cell Signaling) supplemented with 5mM 
NA3VO4 and Complete protease inhibitor (Roche). For PP2 pretreatment, cells were incubated 
with PP2 for 20 hours prior to lysis. Lysates were precleared with protein G Dynabeads 
(Invitrogen) followed by an overnight incubation with antibody-coupled protein G Dynabeads. 
Antibodies used were: anti-ABL1 (24-11) (Santa Cruz Biotechnology), anti-MAD2L1 (D8A7) (Cell 
Signaling) and anti-phospho-tyrosine (4G10) (Millipore).  
 
Immunofluorescence 
Transfected wells were transferred to poly-L-lysine coated cover slips. The next day, cells were 
fixed with 4% paraformaldehyde and permeabilized in 0.2% Triton X-100. Cells were stained 
using the following antibodies: anti-ABL1 (clone 8E9) (BD Biosciences), anti-SMC4 (D14E2) (Cell 
Signaling), Alexa Fluor 488 conjugated anti-mouse IgG, and Alexa Fluor 555 conjugated anti-
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rabbit IgG (Invitrogen). Cells were examined on a Leica TCS SP5 II (Leica Microsystems) 
confocal microscope. Images were analyzed in ImageJ. 
 
RESULTS 
SRC family kinases can be activated by BCR-ABL1 and are therapeutic targets in imatinib 
resistant CML.14 Therefore, we wanted to investigate whether SRC family kinases could also play 
an essential role in supporting proliferation and survival of NUP214-ABL1 positive T-ALL cells. 
We treated the human NUP214-ABL1 positive T-ALL cell line ALL-SIL as well as the NUP214-
ABL1 negative T-ALL cell lines JURKAT and SUP-T1 with increasing concentrations of the SRC 
family kinase inhibitor PP2. Proliferation of ALL-SIL cells was completely inhibited in the presence 
of 5µM PP2. However, 5µM of PP2 caused no or a very minor effect on the proliferation of the 
NUP214-ABL1 negative control cell lines (Figure 1A). Likewise, PP2 had no significant effects on 
cell viability and apoptosis in these cells (Figure 1B). In contrast, a clear dose-dependent 
increase in the amount of apoptotic and dead cells was observed in response to PP2 in the 
NUP214-ABL1 positive ALL-SIL cells (Figure 1B). These results support that ALL-SIL cells 
depend on the activity of SRC family kinases. To verify that this effect was not restricted to the 
single NUP214-ABL1 positive ALL-SIL cell line, we also tested the effect of SRC family kinase 
inhibition in a collection of mouse T-cell leukemia cell lines. In agreement with the data obtained 
in the human cell lines, PP2 inhibited proliferation and induced apoptosis in the NUP214-ABL1 
positive mouse cell lines NA10073 and NA10075, whereas the NUP214-ABL1 negative lines L-
5178-Y and RLD-1 were unaffected (Figure 1C-1D). Notably, the effect of SRC family kinase 
inhibition was stronger in the mouse lines, where a concentration of 1µM PP2 already induced a 
drastic reduction of cell proliferation and survival. 
 
To delineate the identity of the SRC family kinase(s) responsible for the sensitivity of ALL-SIL 
cells to PP2, we investigated the expression of eight SRC kinase family members in these cells 
by qRT-PCR. ALL-SIL only expressed significant levels of LCK and FYN (Figure 2A). In 
agreement with this, LCK and FYN protein was detectable in ALL-SIL cells (Figure 2B). 
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However, when we assessed the activation state of LCK and FYN in ALL-SIL cells by testing 
phosphorylation on their activation loops, we only found LCK to be robustly phosphorylated and 
this phosphorylation was inhibited by PP2 in a dose-dependent manner. In contrast, 
phosphorylation of the activation loop of FYN was virtually undetectable, even in the absence of 
PP2 (Figure 2B). These observations indicate that only LCK kinase activity contributed to 
survival and proliferation of ALL-SIL cells. 
 
As an alternative way to perturb SRC family kinase signaling, we performed siRNA knock-down 
experiments of LCK and FYN in ALL-SIL cells. As a positive control, we also knocked-down 
ABL1, which drastically interfered with the proliferation and viability of the NUP214-ABL1 
dependent ALL-SIL cells (Figure 2C-2D). Knock-down of LCK strongly inhibited ALL-SIL cell 
proliferation and viability, although to a lesser extent than knock-down of ABL1 (Figure 2C-2D). 
This may be explained by the lower knock-down efficiencies that could be achieved for LCK as 
compared to ABL1 (Supplementary Figure 1). In contrast, knock-down of LCK in NUP214-ABL1 
negative JURKAT cells did not affect proliferation and viability of these cells, suggesting that 
dependence on LCK was specific for NUP214-ABL1 expressing cells (Figure 2C-2D). Treatment 
with FYN siRNA induced only a slight but significant reduction in proliferation of ALL-SIL cells but 
did not affect their viability. We also tested the effects of Lck knock-down in mouse T-cell 
leukemia cell lines, using an independent mouse Lck siRNA. In agreement with the data in the 
human cell lines, knock-down of Lck reduced the proliferation and survival of the NUP214-ABL1 
positive cell line NA10075, whereas these effects were not observed in the NUP214-ABL1 
negative cell line L-5178-Y (Figure 2E-2F). Unfortunately, the NA10073 and RLD-1 mouse cell 
lines that we used for the experiments shown in Figure 1C-D could not be included as adequate 
siRNA knock-down in these cells could not be obtained. Taken together, our results indicate that 
NUP214-ABL1 positive human and mouse cells strongly depend on the expression and activity of 
LCK for their proliferation and survival and that therapeutic inhibition of LCK activity may provide 
an alternative means of treating NUP214-ABL1 positive T-ALL. 
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We next set out to identify proteins, in addition to LCK, that are required for the proliferation and 
survival of NUP214-ABL1 expressing cells and could possibly be exploited for therapeutic 
targeting. We used an unbiased approach to study the composition of cellular NUP214-ABL1 
complexes by mass spectrometry based interaction proteomics. For this, NUP214-ABL1 (along 
with ABL1) and its interacting proteins were immunoprecipitated with an anti-ABL1 antibody from 
ALL-SIL cells followed by mass spectrometric analysis of proteins in the precipitated complexes 
(Figure 3A). The MS results were searched against the human International Protein Index (IPI) 
database18 to yield a primary dataset of 289 proteins (Supplementary Table 2). From this list, 
nine potential specific NUP214-ABL1 interactors were selected (Table 1). This was achieved by 
comparing the proteins identified in the immunoprecipitated samples with the most abundant 
proteins identified from total cell lysates (i.e. ‘core’ proteomes)19 and removing ABL1 interactors. 
This method was previously developed to identify specific interactors of BCR-ABL1.16 Notably, 
the nine selected candidate NUP214-ABL1 interactors were very rarely observed when screened 
against an extensive internally curated interactor database. This database has been generated 
from numerous interaction proteomics experiments performed with hundreds of different bait 
proteins from a range of different cell lines. This finding thus implicated these particular proteins 
as specific interactors of NUP214-ABL1. Interestingly, the list of nine candidate NUP214-ABL1 
interacting proteins did not show any overlap with the BCR-ABL1 interactors that were recently 
characterized using a similar experimental design,16 further decreasing the likelihood that the 
identified proteins were interacting with endogenous ABL1, which was inevitably co-
immunoprecipitated with NUP214-ABL1 in this experimental approach. 
 
To investigate if any of the nine NUP214-ABL1 interactors is required for proliferation and/or 
viability of NUP214-ABL1 positive cells, we performed siRNA knock-down of each of these 
proteins in ALL-SIL cells. Knock-down of DOCK2, ABI1, MAD1L1, STAT1 or WASF2 did not 
significantly reduce the proliferation and viability of ALL-SIL cells. In contrast, knock-down of 
NUP155, MAD2L1 and SMC4 strongly inhibited proliferation and survival as compared to 
scrambled control siRNA treated cells (Figure 3B-C). Minor effects were observed upon EVL 
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knock-down. To distinguish NUP214-ABL1 specific effects from a general requirement of these 
proteins for cellular proliferation and survival, we also knocked-down NUP155, MAD2L1 and 
SMC4 in three T-ALL cell lines that do not express NUP214-ABL1 (KE-37, JURKAT and RPMI-
8402), as well as in a BCR-ABL1 positive CML cell line (K-562). Knock-down of NUP155 did not 
significantly affect the proliferation of these control cell lines, whereas knock-down of MAD2L1 or 
SMC4 did cause minor effects on cell proliferation, albeit much less pronounced than in the ALL-
SIL cells (Figure 3D). Moreover, whereas cell viability of ALL-SIL cells was drastically reduced by 
knock-down of NUP155, MAD2L1 and SMC4, cell viability of the NUP214-ABL1 negative lines 
was unaffected by knock-down of each of these proteins (Figure 3E). We also knocked-down 
MAD2L1, NUP155, or SMC4 in mouse T-cell leukemia cell lines, using an independent set of 
mouse siRNAs. In agreement with the data obtained in the human cell lines, knock-down of these 
interaction partners specifically reduced the proliferation of the NUP214-ABL1 positive cell line 
NA10075, whereas these effects were not observed in the NUP214-ABL1 negative cell line L-
5178-Y (Figure 3F). Taken together, our results indicate that NUP214-ABL1 positive cells show a 
dependence for their proliferation and survival on MAD2L1, NUP155 and SMC4.  
 
Next, we tried to confirm binding of MAD2L1, NUP155, and SMC4 to NUP214-ABL1 in 
independent co-immunprecipitation (co-IP) experiments. We could co-IP endogenous NUP214-
ABL1 with endogenous MAD2L1 in NUP214-ABL1 positive ALL-SIL cells. This interaction was 
absent in NUP214-ABL1 negative JURKAT cells or BCR-ABL1 positive K-562 cells, indicating a 
specific interaction of NUP214-ABL1 with MAD2L1 (Figure 4A). We were however unable to 
confirm interactions with endogenous NUP155 or SMC4 due to technical limitations concerning 
the antibodies that were available for these interacting proteins. To circumvent these limitations, 
further interaction studies were performed in HEK293T cells, where we expressed NUP214-ABL1 
in combination with HA-tagged NUP155 or SMC4. Under these conditions, we were able to co-IP 
NUP155 with NUP214-ABL1 (Figure 4B). Of note, we also detected a very weak interaction with 
BCR-ABL1. However, taking into account that BCR-ABL1 was immunoprecipitated in much larger 
quantities than NUP214-ABL1, our data indicated a specific interaction between NUP214-ABL1 
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and NUP155. An interaction between SMC4 and NUP214-ABL1 could not be detected by Co-IP. 
However, in immunofluorescence experiments, we observed that expression of NUP214-ABL1 in 
HEK293T cells causes a redistribution of endogenous SMC4 from diffuse cytoplasmic and 
nuclear staining in control cells towards co-localization at the nuclear envelope upon expression 
of NUP214-ABL1, strongly pointing to an, at least indirect, interaction between NUP214-ABL1 
and SMC4 (Figure 4C). 
 
DISCUSSION 
The discovery of the ABL1 kinase inhibitor imatinib, the first successful example of molecularly 
tailored therapy, has revolutionized the treatment of BCR-ABL1 positive CML and B-ALL, as well 
as of other tumors that depend on imatinib sensitive tyrosine kinases.20 It is now well established 
that also the oncogenic NUP214-ABL1 fusion kinase is sensitive to imatinib and that proliferation 
of cell lines expressing NUP214-ABL1 is inhibited by imatinib.4,6,8 However, we still await more 
clinical experience to evaluate the therapeutic potential of imatinib in NUP214-ABL1 positive T-
ALL. Because of the low number of patients carrying the NUP214-ABL1 fusion, reports on the 
clinical responses of those patients are limited so far. In human T-ALL patients, NUP214-ABL1 
invariably shows intra- or extra-chromosomal amplification, with as many as 20-30 copies per 
cell.4,21 As overexpression of BCR-ABL1 is a known mechanism of imatinib resistance,22-25 we 
predict that this amplification of NUP214-ABL1 may contribute to imatinib resistance in NUP214-
ABL1 positive T-ALL. Another well-known mechanism of resistance to imatinib in BCR-ABL1 
positive leukemias is the emergence of resistance due to point mutations,9 a phenomenon that 
we also expect in NUP214-ABL1 positive T-ALL. In this study, we therefore aimed at identifying 
proteins in the signaling and interaction network of NUP214-ABL1 that are critical for the survival 
and proliferation of T-ALL cells, as these proteins might serve as alternative drug targets in 
imatinib resistant NUP214-ABL1 positive T-ALL.  
 
BCR-ABL1 activates the SRC family kinases LYN, FGR and HCK in pre-B-cells and these 
kinases are required for B-ALL induction by BCR-ABL1 in a mouse model.15 Moreover, imatinib 
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resistant BCR-ABL1 positive CML blast crisis cells can be forced into apoptosis by targeting 
LYN.14 Based on these results, we hypothesized that SRC family kinases may also play an 
important role in NUP214-ABL1 mediated transformation. Indeed, we found that NUP214-ABL1 
positive human and mouse cell lines are sensitive to the SRC family kinase inhibitor PP2, which 
is primarily mediated through inhibition of LCK. LCK is a central kinase in T-cell precursors for the 
transition of CD4/CD8 double negative to double positive thymocytes and stimulates mitosis of 
early T-cell precursors.26 Moreover, mice transgenic for wild type or constitutively active Lck 
develop thymic tumors and rare T-ALL cases have been described with overexpression of LCK 
by t(1;7)(p34;q34) juxtaposing LCK to the strong promoter sequences of the TRB@ locus.27,28 
These data, together with our finding of required LCK activity for proliferation of NUP214-ABL1 
transformed cells, establish LCK as an important drug target in the pathogenesis of T-ALL.  
 
Our finding that LCK is required for NUP214-ABL1 in T-ALL has clinical implications. The FDA-
approved multi-kinase inhibitors dasatinib and bosutinib inhibit both ABL and SRC kinases and 
are used for the treatment of imatinib-resistant and -sensitive BCR-ABL positive 
malignancies.29,30 Interestingly, both drugs very potently inhibit LCK activity in vitro with IC50 
values of ~1-2 nM.31,32 We showed that NUP214-ABL1 activity is inhibited by dasatinib in in vitro 
kinase assays, that proliferation of NUP214-ABL1 positive cells is inhibited by dasatinib and that 
dasatinib inhibits NUP214-ABL1 positive leukemogenesis in mouse xenografts and primary 
NUP214-ABL1 positive T-ALL lymphoblasts.6,9 Furthermore, dasatinib and bosutinib have a much 
narrower spectrum of point mutations that cause drug resistance as compared to imatinib.33 The 
clinical potential of dasatinib or bosutinib for the treatment of NUP214-ABL1 positive T-ALL is 
further supported by a case report showing induction of rapid complete hematologic and 
cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1 
positive T-ALL.34 Based on this diverse pre-clinical and emerging clinical data, one may prefer 
dasatinib over imatinib in NUP214-ABL1 positive T-ALL patients. Ideally, efficacy of dual SRC-
ABL1 inhibitors versus ABL1 inhibitors should now be compared in experiments with primary 
NUP214-ABL1 positive leukemia cells.  
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We previously described that NUP214-ABL1 and BCR-ABL1, despite carrying the same portion 
of the ABL1 kinase, differ in almost any biological property that we have studied such as 
subcellular localization, mechanism of initiation of kinase activity, phosphorylation pattern, 
enzymatic activity, kinase inhibitor sensitivity and substrate spectrum.6,7 Analysis of the proteins 
interacting with NUP214-ABL1 in this work again indicates a strong difference from BCR-ABL1. 
None of the core interaction partners that we identified for BCR-ABL1 (GRB2, SHC1, CRK-I, 
CBL, p85, STS-1, and SHIP-2) were identified in the mass spectrometric analysis of the NUP214-
ABL1 protein complexes.16 This dramatically different composition of NUP214-ABL1 and BCR-
ABL1 complexes might be a combination of the T-cell versus granulocyte/B-cell context in which 
NUP214-ABL1 and BCR-ABL1 are occurring, conformational differences of the ABL1 portion of 
the two fusion oncoproteins and the differences in their subcellular localizations. NUP214-ABL1 is 
partially residing at the cytoplasmic side of the nuclear envelope and in the cytoplasm whereas 
BCR-ABL1 localizes strictly cytoplasmic.7 The mass spectrometric studies on the BCR-ABL1 
protein complexes16 were performed under the same conditions and in the same lab as the 
NUP214-ABL1 complexes. Thus, it can be excluded that the observed differences between BCR-
ABL1 and NUP214-ABL1 are due to different immunoprecipitation or mass spectrometry 
conditions. We also confirmed that BCR-ABL1 core interactors were expressed in NUP214-ABL1 
positive cells and vice versa, excluding that the absence of interaction of BCR-ABL1 interactors 
with NUP214-ABL1 is caused by a lack of expression of these proteins in NUP214-ABL1 positive 
cells and vice versa. 
 
In this study, we identified NUP155 as an interactor of NUP214-ABL1 and knock-down of 
NUP155 reduced proliferation of NUP214-ABL1 positive cells. These data fit within our previous 
observations that NUP214-ABL1 interacts with other nucleoporins such as NUP62, NUP88 and 
RANBP2 (= NUP358) and that NUP214-ABL1 depends on interaction with these nucleoporins for 
its activity.7 In contrast to NUP62, NUP88 and RANBP2, no direct interactions between NUP214 
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and NUP155 have been described. However, our data indicate that in the context of NUP214-
ABL1, NUP155 is interacting with NUP214 (directly or indirectly) in the nuclear pore complex. 
 
In addition to NUP155, also SMC4, a member of the condensing complex converting interphase 
chromatin into condense chromosomes, and MAD2L1, a spindle checkpoint regulator protecting 
cells from abnormal chromosome segregation, were detected in NUP214-ABL1 complexes and 
were required for proliferation of NUP214-ABL1 positive cells. It remains to be determined if 
NUP155, SMC4 and MAD2L1 are substrates phosphorylated by NUP214-ABL1 and if so, 
whether the function of these proteins is affected in NUP214-ABL1 positive cells. Preliminary 
experiments failed to detect NUP214-ABL1-dependent tyrosine phosphorylation of these three 
proteins (Supplementary Figure 4). Another mechanism by which NUP214-ABL1 could affect 
the function of these proteins is by altering their subcellular localization. Indeed, for SMC4 we 
observed a clear change in localization of the cellular SMC4 pool towards the nuclear envelope. It 
will be interesting to test how this affects SMC4 function. Based on the role of SMC4 and 
MAD2L1 in cellular processes such as in chromosome condensation and spindle checkpoint 
regulation, it is not unlikely that altered function of these proteins promotes transformation of cells 
by NUP214-ABL1. 
 
It is worth to note that in our interaction proteomics studies, we were able to confirm known 
interactions of NUP214-ABL1 with NUP88 and PTPN2.7,35 PTPN2 is a phosphatase that we 
previously found deleted in T-ALL and which we showed to negatively regulate NUP214-ABL1 
tyrosine kinase activity.35 Interestingly, we also identified STAT1 as a member of NUP214-ABL1 
protein complexes. Endogenous NUP214 is known to import STAT1 in the nucleus under normal 
steady state conditions.36 Our knock-down studies, however, suggest that NUP214-ABL1 positive 
cells do not depend on STAT1 for their survival.  
 
As mentioned earlier, the NUP214-ABL1 fusion was recently described to also occur in B-ALL 
patients.5,37 At this moment it remains to be determined to what extent NUP214-ABL1 in T-ALL 
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and B-ALL context resemble each other and whether the findings we describe above in the 
context of T-ALL cells could also be applicable to B-ALL. 
 
NUP214-ABL1 usually presents with episomal amplification where the number of copies varies 
considerably from cell to cell in the same patient.4,21 In some patients, it even occurs as a 
secondary change not seen in all cells. Therefore, to obtain durable therapeutic responses in 
NUP214-ABL1 positive T-ALL, we anticipate that combinations of agents hitting NUP214-ABL1 
and/or the proteins on which NUP214-ABL1 relies, together with other targeted agents and/or low 
doses of chemotherapy will be required.  
 
In conclusion, we identify LCK, MAD2L1, SMC4 and NUP155 as proteins on which NUP214-
ABL1 positive T-ALL tumor cells critically depend for their proliferation, identifying these proteins 
as potential drug targets in NUP214-ABL1 positive T-ALL. Targeting LCK in NUP214-ABL1 could 
easily be addressed in the clinical treatment schemes of NUP214-ABL1 positive T-ALL patients, 
due to the availability of dasatinib and bosutinib co-targeting ABL1 and LCK. Our work thus 
provides a molecular rationale for testing dasatinib and bosutinib alone or in combination with 
other targeted agents and/or chemotherapy in patients with NUP214-ABL1 positive T-ALL. 
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TABLES 
Table 1. List of selected potential NUP214-ABL1 interactors   
The column ‘peptides’ refers to the number of unique peptides that were identified for that 
corresponding protein in the mass spectrometry analysis. ‘Coverage’ refers to the % of sequence 
of the total protein that was identified in our mass spectrometry analysis. 
 
Gene  Full Gene Name Peptides Coverage (%) 
NUP155 Nucleoporin 155 kDa 33 30.7 
DOCK2 Dedicator Of Cytokinesis 2 3 1.7 
EVL Enah/Vasp-like 5 14.4 
ABI1 ABL-Interactor 1 3 8.5 
MAD1L1 Mitotic Arrest Deficient 1-like 1 (yeast) 10 16.7 
MAD2L1 Mitotic Arrest Deficient 2-like 1 (yeast) 2 8.8 
STAT1 Signal Transducer and Activator of Transcription 1 4 6.6 
SMC4 Structural Maintenance of Chromosomes 4 4 3.8 
WASF2 WAS protein Family, member 2 3 6.6 
 
 
 
FIGURE LEGENDS 
Figure 1. NUP214-ABL1 positive T-ALL cell lines are sensitive to inhibition of SRC kinases 
(A) Human NUP214-ABL1 positive (ALL-SIL) and negative (JURKAT and SUP-T1) T-ALL cell 
lines were treated with indicated concentrations of PP2. Cell proliferation was normalized to 
DMSO treated cells. The average ±SD of three repeats is shown. (B) Percentages of viable, 
apoptotic, and dead cells after PP2 treatment were determined by Annexin-V/7-AAD staining.  (C) 
Mouse NUP214-ABL1 positive (NA10073 and NA10075) and negative (L5178Y and RLD1) T-cell 
lines were treated with indicated concentrations of PP2 for 48 hours. Cell proliferation was 
normalized to DMSO treated cells. The average ±SD of three repeats is shown. (D) Percentages 
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of viable, apoptotic, and dead cells after PP2 treatment were determined by Annexin-V/7-AAD 
staining. 
 
Figure 2. LCK is critical for NUP214-ABL1 positive T-ALL cell lines.  
(A) qRT-PCR analysis of SRC family kinase expression in ALL-SIL cells. (B) Immunoprecipitation 
of LCK or FYN from ALL-SIL cell lysates. Cells were pretreated with indicated concentrations of 
PP2 inhibitor. Phosphorylation of the precipitated proteins was assessed with an anti-phospho-
SRC family kinase (Tyr416) antibody. (C) Proliferation of NUP214-ABL1 positive (ALL-SIL) and 
NUP214-ABL1 negative (JURKAT) cells after electroporation with indicated siRNAs. The average 
±SD of triplicates is shown. (D) Percentages of viable cells after electroporation with indicated 
siRNAs. (E) Proliferation of NUP214-ABL1 positive (NA10075) and NUP214-ABL1 negative 
(NA10073) cells after electroporation with indicated siRNAs. The average ±SD of triplicates is 
shown. (F)  Percentages of viable cells after electroporation with indicated siRNAs. siRNA knock-
down efficiencies are displayed in Supplementary Figure 1 and 2. 
Figure 3. MAD2L1, NUP155 and SMC4 are required for optimal proliferation of NUP214-
ABL1 positive T-ALL cell lines.  
(A) Overview of the mass spectrometry approach that was used to identify interactor proteins of 
NUP214-ABL1. ALL-SIL cells were lysed, resulting in the release of all cellular proteins and 
protein complexes. NUP214-ABL1 and its interacting proteins were isolated by using anti-ABL1 
antibody coupled beads. The isolated NUP214-ABL1 complexes were characterized by mass 
spectrometry to determine the identity of NUP214-ABL1 interacting proteins. (B) Cell proliferation 
of NUP214-ABL1 positive ALL-SIL cells after electroporation with indicated siRNAs. Cell 
proliferation measurements were normalized to the scrambled control. (C) Cell viability of ALL-SIL 
cells after electroporation with indicated siRNAs. (D) Proliferation of NUP214-ABL1 negative KE-
37, RPMI-8402, JURKAT and K-562 cells after electroporation with indicated siRNAs. Cell 
proliferation was normalized to scrambled control. (E) Cell viability of NUP214-ABL1 positive ALL-
SIL cells and of NUP214-ABL1 negative KE-37, RPMI-8402, JURKAT and K-562 cells after 
electroporation with indicated siRNAs. (F) Proliferation of mouse NUP214-ABL1 positive 
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(NA10075) NUP214-ABL1 negative (L-5178-Y) cells after electroporation with indicated siRNAs. 
Cell proliferation was normalized to scrambled control. The average ±SD of three repeats is 
shown for all siRNA knock-down experiments. siRNA knock-down efficiencies are displayed in 
Supplementary Figure 3. 
 
Figure 4. MAD2L1, NUP155 and SMC4 interact or colocalize with NUP214-ABL1.  
(A) Endogenous MAD2L1 protein was immunoprecipitated from ALL-SIL (NUP214-ABL1 
positive), K-562 (BCR-ABL1 positive) and JURKAT cells (no ABL1 fusion) with anti-MAD2L1 
antibody. Co-IP of NUP214-ABL1 or BCR-ABL1 was assessed on the shown western blot with 
anti-ABL1 antibody. (WCL: whole cell lysate) (B) ABL1 protein was immunoprecipitated from 
HEK293T cells that were transfected with the indicated combinations of NUP155-HA and ABL1 
fusion constructs. Co-precipitation of HA-tagged NUP155 was assessed with anti-HA antibody. 
(C) Subcellular localization of NUP214-ABL1, ABL1 and SMC4 was investigated by 
immunofluorescence in HEK293T cells. Control HEK293T cells display low endogenous levels of 
ABL1 and diffuse SMC4 staining. In contrast, ABL1 and SMC4 co-localize at the nuclear pore in 
transfected cells expressing NUP214-ABL1. DRAQ5 stains DNA and visualizes the nucleus. 
Scale bar: 5µm   
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Suppl. Figure 1. siRNA knock-down levels in human T-ALL cells. 
Western blot analysis of ALL-SIL (A) and JURKAT (B) cells treated with indicated siRNAs. The western blots were 
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Suppl. Figure 2. siRNA knock-down levels of Lck in mouse T-ALL cells. 
Lck knock-down levels were measured by qRT-PCR in mouse L-5178-Y cells treated with control scrambled
siRNA, or Lck siRNA. Indicated levels are relative to scrambled control siRNA treated cells (0% knock-down).
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Suppl. Figure 4. No detectable tyrosine phosphorylation of MAD2L1, SMC4 and NUP155 . 
Immunoprecipitation (IP) using a pan-phospho-tyrosine (anti-P-Tyr) antibody on ALL-SIL, K562 and JURKAT cell lysates 
pulled down phosphorylated NUP214-ABL1 (in ALL-SIL) and BCR-ABL1 (in K-562) as detected on the western blot with 
the anti-phospho-ABL1 (Tyr 245) antibody. NUP214-ABL1 interaction partners MAD2L1, SMC4 and NUP155 were not 
detectable in the IP samples indicating these proteins may not be phosphorylated.
Supplementary table 1. siRNA sequences used in this study   
Target Gene Species Type Sequence 
ABL1 Human Invitrogen Stealth GGAAUGGUGUGAAGCCCAAACCAAA 
LCK Human Invitrogen Stealth GCAUUCAUUGAAGAGCGGAAUUAUA 
FYN Human Invitrogen Stealth CCCUGUACGGGAGGUUCACAAUCAA 
NUP155 Human Invitrogen Stealth CCGAUGGUGAAUUUCUUCAUGAAUU 
DOCK2 Human Invitrogen Stealth CGACAUGAUGCUGUGUGAAUAUCAA 
EVL Human Invitrogen Stealth GCAGCAGCGUCAGGAAUCUCUAGAA 
ABI1 Human Invitrogen Stealth ACUGGGACGGAAUACUCCUUAUAAA 
MAD1L1 Human Invitrogen Stealth GAAGACCUUUCCAGAUUCGUGGUUG 
MAD2L1 Human Invitrogen Stealth GCCACUGUUGGAAGUUUCUUGUUCA 
STAT1 Human Invitrogen Stealth GCAAGCGUAAUCUUCAGGAUAAUUU 
SMC4 Human Invitrogen Stealth CAGGGUGAAGUUGAACAAAUUGCUA 
WASF2 Human Invitrogen Stealth CCCAUCUUUCCCACCUCACCCUGAU 
Lck Mouse IDT Screening DsiRNA GUAAUUCUGUUCUUCGAUGAACGCCAU 
Mad2L1 Mouse Ambion Silencer Select UUGUAAAUGAGCGUAGACGga 
Nup155 Mouse Ambion Silencer Select AUUCGAAGAAAAGUAAAUGCaa 
Smc4 Mouse Ambion Silencer Select UGCUGUAUUAUGUCGACUGag 
Scrambled Human Invitrogen Stealth Available on request: #12935100 
Scrambled Mouse IDT CGUUAAUCGCGUAUAAUACGCGUat 
Scrambled Mouse Ambion Silencer Select Available on request #4390847 
Supplementary Table 2. Complete list of proteins identified by mass spectrometry
Name Description Synonyms Sequence-ID # Peptides % Sequence Coverage
ABL1 "v-abl Abelson murine leukemia viral oncogene homolog 1" ABL, JTK7, p150, c-ABL, v-abl NP_005148 37 37,8
NUP155 "nucleoporin 155kDa" N155, KIAA0791 NP_004289 33 30,7
DNCH1 "dynein, cytoplasmic, heavy polypeptide 1" p22, DHC1, DNCL, DYHC, HL-3, DHC1a, DNECL, Dnchc1, KIAA0325 NP_001367 26 6,3
CYFIP2 "cytoplasmic FMR1 interacting protein 2" PIR121, PRO1331 NP_055191 21 19,6
SPTBN1 "spectrin, beta, non-erythrocytic 1" SPTB2 NP_842565 21 11,6
TLN1 "talin 1" TLN, KIAA1027 NP_006280 20 9,7
VCP "valosin-containing protein" p97, TERA, IBMPFD NP_009057 16 22,7
TRIM21 "tripartite motif-containing 21" SSA, RO52, SSA1, RNF81 NP_003132 15 33,3
CCT2 "chaperonin containing TCP1, subunit 2 (beta)" CCTB, 99D8.1, PRO1633, CCT-beta, TCP-1-beta NP_006422 11 25,2
CCT4 "chaperonin containing TCP1, subunit 4 (delta)" SRB, Cctd NP_006421 11 23,4
CYFIP1 "cytoplasmic FMR1 interacting protein 1" SHYC, FLJ45151, KIAA0068, P140SRA-1 NP_055423 11 10,4
DLAT "dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex)" DLTA, PDCE2, PDC-E2 NP_001922 11 16,4
HEM1 "hematopoietic protein 1" NP_005328 11 11,4
RPS18 "ribosomal protein S18" KE3, HKE3, KE-3, D6S218E NP_072045 11 56,6
SF3B3 "splicing factor 3b, subunit 3, 130kDa" RSE1, SAP130, SF3b130, STAF130, KIAA0017 NP_036558 11 12,2
BIRC6 "baculoviral IAP repeat-containing 6 (apollon)" BRUCE, APOLLON, FLJ13726, FLJ13786, KIAA1289 NP_057336 10 2,4
MAD1L1 "MAD1 mitotic arrest deficient-like 1 (yeast)" MAD1, PIG9, HsMAD1, TP53I9, TXBP181 NP_003541 10 16,7
PDHA1 "pyruvate dehydrogenase (lipoamide) alpha 1" PDHA, PHE1A, PDHCE1A NP_000275 10 26,2
XRCC5 "X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80kDa)" KU80, Ku86, NFIV, KARP1, KARP-1 NP_066964 10 15,8
ABL2 "v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)" ARG, ABLL NP_005149 9 7,0
PDHB "pyruvate dehydrogenase (lipoamide) beta" PHE1B, DKFZp564K0164 NP_000916 9 34,0
RPS3 "ribosomal protein S3" FLJ26283, FLJ27450, MGC87870 NP_000996 9 44,9
SEPT9 "septin 9" MSF, MSF1, SINT1, PNUTL4, AF17q25, KIAA0991 NP_006631 9 17,6
TRIM28 "tripartite motif-containing 28" KAP1, TF1B, RNF96, TIF1B NP_005753 9 14,0
ALDOA "aldolase A, fructose-bisphosphate" ALDA, MGC10942, MGC17716, MGC17767 NP_908930 8 22,8
KARS "lysyl-tRNA synthetase" KARS2, KIAA0070 NP_005539 8 15,2
TFRC "transferrin receptor (p90, CD71)" TFR, CD71, TFR1, TRFR NP_003225 8 12,5
EEF1G "eukaryotic translation elongation factor 1 gamma" EF1G NP_001395 7 15,8
EIF3S3 "eukaryotic translation initiation factor 3, subunit 3 gamma, 40kDa" eIF3-p40, MGC102958, eIF3-gamma NP_003747 7 23,6
HSPD1 "heat shock 60kDa protein 1 (chaperonin)" CPN60, GROEL, HSP60, HSP65, SPG13, HuCHA60 NP_002147 7 16,9
IDH2 "isocitrate dehydrogenase 2 (NADP+), mitochondrial" IDH, IDP, IDHM, ICD-M, mNADP-IDH NP_002159 7 18,4
ILF3 "interleukin enhancer binding factor 3, 90kDa" DRBF, MMP4, MPP4, NF90, NFAR, TCP80, DRBP76, NFAR-1, MPHOSPH4, NF-AT-90 NP_703194 7 12,8
PGK1 "phosphoglycerate kinase 1" PGKA, MIG10, MGC8947 NP_000282 7 24,0
RPL6 "ribosomal protein L6" TXREB1, TAXREB107 NP_000961 7 22,9
RPS19 "ribosomal protein S19" DBA NP_001013 7 41,4
SEPT2 "septin 2" DIFF6, NEDD5, hNedd5, KIAA0158 NP_004395 7 24,7
EWSR1 "Ewing sarcoma breakpoint region 1" EWS NP_005234 6 10,8
HPRT1 "hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome)" HPRT, HGPRT NP_000185 6 31,7
HRMT1L2 "HMT1 hnRNP methyltransferase-like 2 (S. cerevisiae)" ANM1, HCP1, IR1B4, PRMT1 NP_938074 6 19,2
ILF2 "interleukin enhancer binding factor 2, 45kDa" NF45, MGC8391, PRO3063 NP_004506 6 20,3
LOC641814 ipi|IPI00735235 6 20,6
LOC646483 ipi|IPI00742225 6 20,7
MYL6 "myosin, light polypeptide 6, alkali, smooth muscle and non-muscle" ESMLC, LC17A, LC17B, MLC1SM, MLC3NM, MLC3SM, LC17-GI, LC17-NM ipi|IPI00744444 6 35,9
PFN1 "profilin 1" NP_005013 6 46,4
PHGDH "phosphoglycerate dehydrogenase" PDG, PGD, PGAD, PGDH, SERA, 3PGDH, 3-PGDH, MGC3017 NP_006614 6 13,3
PSMC2 "proteasome (prosome, macropain) 26S subunit, ATPase, 2" S7, MSS1, MGC3004 NP_002794 6 15,9
RPL4 "ribosomal protein L4" HRPL4 NP_000959 6 16,2
RPN1 "ribophorin I" RBPH1, DKFZp686B16177 NP_002941 6 12,4
RUVBL1 "RuvB-like 1 (E. coli)" ECP54, TIP49, NMP238 NP_003698 6 18,2
SEPT6 "septin 6" SEP2, KIAA0128, MGC16619, MGC20339, RP5-876A24.2 NP_665798 6 16,6
UGP2 "UDP-glucose pyrophosphorylase 2" UDPG, UGPP2, UDPGP2, pHC379 NP_006750 6 16,1
CAPZA1 "capping protein (actin filament) muscle Z-line, alpha 1" CAPZ, CAZ1, CAPPA1 NP_006126 5 26,2
COPB "coatomer protein complex, subunit beta" DKFZp761K102 NP_057535 5 5,7
CORO1A "coronin, actin binding protein, 1A" p57, TACO, CLABP, HCORO1, CLIPINA, FLJ41407, Clabp TACO NP_009005 5 12,1
DARS "aspartyl-tRNA synthetase" DKFZp781B11202 NP_001340 5 10,6
EIF3S7 "eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa" MGC17258, eIF3-p66, eIF3-zeta NP_003744 5 9,9
EVL "Enah/Vasp-like" RNB6 NP_057421 5 14,4
LOC388339 "similar to ribosomal protein S18" LOC388339 ipi|IPI00397609 5 26,3
MTHFD1 "methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase" MTHFC, MTHFD NP_005947 5 6,5
PSMB8 "proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)" LMP7, D6S216, RING10, D6S216E, MGC1491 NP_683720 5 22,1
RAN "RAN, member RAS oncogene family" TC4, ARA24 NP_006316 5 24,5
RPL13 "ribosomal protein L13" BBC1, D16S444E, MGC71373 NP_150254 5 22,7
RPL3 "ribosomal protein L3" TARBP-B NP_000958 5 17,1
RPS14 "ribosomal protein S14" EMTB NP_005608 5 37,7
RUVBL2 "RuvB-like 2 (E. coli)" ECP51, TIP48, CGI-46, TIP49B NP_006657 5 12,1
SEPT1 "septin 1" LARP, SEP1, DIFF6, PNUTL3, MGC20394 NP_443070 5 16,3
SRP14 "signal recognition particle 14kDa (homologous Alu RNA binding protein)" ALURBP, MGC14326 NP_003125 5 34,6
SRP68 "signal recognition particle 68kDa" NP_055045 5 8,0
TKT "transketolase (Wernicke-Korsakoff syndrome)" TKT1 NP_001055 5 12,2
ACOT7 "brain acyl-CoA hydrolase" BACH, ACT, ACH1, LACH1, hBACH, CTE-II, MGC1126, RP1-120G22.10 NP_863656 4 15,5
C22orf28 "hypothetical protein HSPC117" HSPC117, DJ149A16.6, RP1-149A16.6 NP_055121 4 8,7
CFL1 "cofilin 1 (non-muscle)" CFL NP_005498 4 33,7
FAM61A "family with sequence similarity 61, member A" C19orf13, DKFZP434D1335 NP_056393 4 6,7
GSR "glutathione reductase" MGC78522 NP_000628 4 10,9
HIST1H2AB "histone 1, H2ab" H2A/m, H2AFM NP_003504 4 35,4
HIST1H2AC "histone 1, H2ac" H2A/l, H2AFL, MGC99519, dJ221C16.4 NP_003503 4 35,4
HIST1H2AE "histone 1, H2ae" H2A.1, H2A.2, H2A/a, H2AFA NP_066390 4 35,4
HIST1H4A "histone 1, H4a" H4/a, H4FA NP_003529 4 40,8
HIST1H4B "histone 1, H4b" H4/I, H4FI NP_003535 4 40,8
HIST1H4C "histone 1, H4c" H4/g, H4FG, dJ221C16.1 NP_003533 4 40,8
HIST1H4D "histone 1, H4d" H4/b, H4FB, HIST1H4F, dJ221C16.9 NP_003530 4 40,8
HIST1H4E "histone 1, H4e" H4/j, H4FJ NP_003536 4 40,8
HIST1H4F "histone 1, H4f" H4, H4/c, H4FC NP_003531 4 40,8
HIST1H4H "histone 1, H4h" H4/h, H4FH NP_003534 4 40,8
HIST1H4I "histone 1, H4i" H4M, H4/m, H4FM NP_003486 4 40,8
HIST1H4J "histone 1, H4j" H4/e, H4FE, dJ160A22.2 NP_068803 4 40,8
HIST1H4K "histone 1, H4k" H4/d, H4FD, dJ160A22.1 NP_003532 4 40,8
HIST1H4L "histone 1, H4l" H4.k, H4/k, H4FK NP_003537 4 40,8
HIST2H4 "histone 2, H4" H4, H4F2, H4FN, FO108 NP_003539 4 40,8
HIST2H4B "histone H4/o" H4/o ipi|IPI00453473 4 40,8
HIST3H2A "histone 3, H2a" MGC3165 NP_254280 4 35,4
HIST4H4 "histone 4, H4" MGC24116 NP_778224 4 40,8
HSPE1 "heat shock 10kDa protein 1 (chaperonin 10)" CPN10, GROES, HSP10 NP_002148 4 35,3
IPO7 "importin 7" RANBP7 NP_006382 4 4,7
LOC729998 ipi|IPI00738381 4 9,6
LOC730754 ipi|IPI00642513 4 21,7
NUP214 "nucleoporin 214kDa" CAN, CAIN, N214, D9S46E NP_005076 4 2,9
PARP1 "poly (ADP-ribose) polymerase family, member 1" PARP, PPOL, ADPRT, ADPRT1, PARP-1, pADPRT-1 NP_001609 4 4,9
PCID1 "dendritic cell protein" hfl-B5, GA17 NP_006351 4 15,8
PSMB3 "proteasome (prosome, macropain) subunit, beta type, 3" HC10-II, MGC4147 NP_002786 4 22,9
PSMD6 "proteasome (prosome, macropain) 26S subunit, non-ATPase, 6" S10, p44S10, KIAA0107, SGA-113M NP_055629 4 10,8
RFC4 "replication factor C (activator 1) 4, 37kDa" A1, RFC37, MGC27291 NP_853551 4 11,8
RPL18 "ribosomal protein L18" NP_000970 4 25,5
RPL27 "ribosomal protein L27" NP_000979 4 36,0
RPL30 "ribosomal protein L30" NP_000980 4 34,8
RPS13 "ribosomal protein S13" NP_001008 4 19,9
RPS17 "ribosomal protein S17" RPS17L1, RPS17L2, MGC72007 NP_001012 4 23,7
RPS23 "ribosomal protein S23" NP_001016 4 29,4
SF3A3 "splicing factor 3a, subunit 3, 60kDa" PRP9, SAP61, SF3a60 NP_006793 4 8,6
SMC4L1 "SMC4 structural maintenance of chromosomes 4-like 1 (yeast)" CAPC, hCAP-C NP_005487 4 3,6
SRP72 "signal recognition particle 72kDa" NP_008878 4 7,6
STAT1 "signal transducer and activator of transcription 1, 91kDa" ISGF-3, STAT91, DKFZp686B04100 NP_644671 4 6,6
THOC4 "THO complex 4" ALY, BEF NP_005773 4 23,3
TLN2 "talin 2" KIAA0320 NP_055874 4 1,8
ABI1 "abl-interactor 1" E3B1, ABI-1, NAP1BP, SSH3BP, SSH3BP1 NP_005461 3 8,5
ACLY "ATP citrate lyase" ATPCL, CLATP NP_001087 3 3,9
ACTR1A "ARP1 actin-related protein 1 homolog A, centractin alpha (yeast)" ARP1 NP_005727 3 10,9
ACTR2 "ARP2 actin-related protein 2 homolog (yeast)" ARP2 NP_005713 3 9,6
C14orf166 "chromosome 14 open reading frame 166" CLE, CGI-99 NP_057123 3 16,0
C3orf10 "chromosome 3 open reading frame 10" MDS027, hHBrk1, HSPC300 NP_060932 3 37,3
CAPZA2 "capping protein (actin filament) muscle Z-line, alpha 2" CAPZ, CAPPA2 NP_006127 3 14,3
COPA "coatomer protein complex, subunit alpha" HEP-COP NP_004362 3 3,4
DDB1 "damage-specific DNA binding protein 1, 127kDa" DDBA, XAP1, XPCE, XPE-BF, UV-DDB1 NP_001914 3 2,7
DDX6 "DEAD (Asp-Glu-Ala-Asp) box polypeptide 6" P54, RCK, HLR2 NP_004388 3 10,0
DOCK2 "dedicator of cytokinesis 2" KIAA0209 NP_004937 3 1,7
EIF3S4 "eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa" EIF3-P42, eIF3-p44, eIF3-delta NP_003746 3 9,1
H2AFJ "H2A histone family, member J" MGC921, FLJ10903 NP_808760 3 27,1
H2AFV "H2A histone family, member V" H2AV, MGC1947, MGC10170, MGC10831 NP_036544 3 20,3
H2AFZ "H2A histone family, member Z" H2AZ, H2A.z, H2A/z NP_002097 3 20,3
HBA1 "hemoglobin, alpha 1" CD31 NP_000549 3 25,4
HBA2 "hemoglobin, alpha 2" HBA1 NP_000508 3 25,4
HIST1H2AD "histone 1, H2ad" H2A.3, H2A/g, H2AFG, HIST1H3D NP_066409 3 26,9
HIST1H2AG "histone 1, H2ag" H2A/p, H2AFP, H2A.1b, pH2A/f NP_066408 3 26,9
HIST1H2AH "histone 1, H2ah" H2A/S, H2AFALii, dJ86C11.1 NP_542163 3 27,3
HIST1H2AI "histone 1, H2ai" H2A/c, H2AFC NP_003500 3 26,9
HIST1H2AJ "histone 1, H2aj" H2A/E, H2AFE, dJ160A22.4 NP_066544 3 27,3
HIST1H2AK "histone 1, H2ak" H2A/d, H2AFD NP_003501 3 26,9
HIST1H2AL "histone 1, H2al" H2A.i, H2A/i, H2AFI, HIST1H2AM, dJ193B12.9 NP_003502 3 26,9
HIST1H2AM "histone 1, H2am" H2A.1, H2A/n, H2AFN, dJ193B12.1 NP_003505 3 26,9
HIST2H2AA "histone 2, H2aa" H2A, H2A.2, H2A/O, H2AFO, H2a-615 NP_003507 3 26,9
HIST2H2AA4 ipi|IPI00216457 3 26,9
HIST2H2AC "histone 2, H2ac" H2A, H2A/q, H2AFQ, MGC74460, H2A-GL101 NP_003508 3 27,1
HNRPC "heterogeneous nuclear ribonucleoprotein C (C1/C2)" C1, C2, HNRNP, SNRPC, hnRNPC, MGC104306, MGC105117 NP_004491 3 11,3
KIAA1797 "KIAA1797" FLJ20375 NP_060264 3 2,1
LOC388344 "similar to ribosomal protein L13; 60S ribosomal protein L13; breast basic conserved protein 1" LOC388344 ipi|IPI00397611 3 12,8
NUP88 "nucleoporin 88kDa" MGC8530 NP_002523 3 5,0
PA2G4 "proliferation-associated 2G4, 38kDa" EBP1, p38-2G4 NP_006182 3 9,1
PDIA6 "protein disulfide isomerase family A, member 6" P5, ERP5, TXNDC7 NP_005733 3 9,5
PGD "phosphogluconate dehydrogenase" 6PGD NP_002622 3 8,3
PRKCSH "protein kinase C substrate 80K-H" PCLD, G19P1, AGE-R2 NP_002734 3 5,9
PSMB4 "proteasome (prosome, macropain) subunit, beta type, 4" HN3, HsN3, PROS26 NP_002787 3 12,9
PSMB9 "proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2)" LMP2, RING12, MGC70470 NP_683756 3 14,8
PTPN2 "protein tyrosine phosphatase, non-receptor type 2" PTPT, TCPTP, TC-PTP, TCELLPTP NP_002819 3 8,2
RBM14 "RNA binding motif protein 14" SIP, COAA, SYTIP1, DKFZp779J0927 NP_006319 3 4,5
RPL35 "ribosomal protein L35" NP_009140 3 26,0
RPL35A "ribosomal protein L35a" NP_000987 3 15,5
RPL38 "ribosomal protein L38" NP_000990 3 31,4
RPL8 "ribosomal protein L8" NP_150644 3 13,6
RPS11 "ribosomal protein S11" NP_001006 3 12,0
RPS5 "ribosomal protein S5" NP_001000 3 18,1
SNRP70 "small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen)" RPU1, U1AP, U170K, U1RNP, RNPU1Z NP_003080 3 6,9
SNRPB "small nuclear ribonucleoprotein polypeptides B and B1" COD, SNRPB1, snRNP-B, SmB/SmB' NP_937859 3 12,5
SNRPN "small nuclear ribonucleoprotein polypeptide N" SMN, SM-D, RT-LI, HCERN3, SNRNP-N, SNURF-SNRPN NP_003088 3 12,5
TMEM137 "hypothetical protein MGC15912" MGC15912 ipi|IPI00013174 3 4,5
WASF2 "WAS protein family, member 2" SCAR2, WAVE2, dJ393P12.2 NP_008921 3 6,6
YARS "tyrosyl-tRNA synthetase" YRS, YTS, tyrRS NP_003671 3 6,6
ABCE1 "ATP-binding cassette, sub-family E (OABP), member 1" RLI, OABP, ABC38, RNS4I, RNASEL1, RNASELI NP_002931 2 4,2
ACTR3 "ARP3 actin-related protein 3 homolog (yeast)" ARP3 NP_005712 2 5,3
ARPC3 "actin related protein 2/3 complex, subunit 3, 21kDa" ARC21, p21-Arc NP_005710 2 13,5
ASCC3L1 "activating signal cointegrator 1 complex subunit 3-like 1" HELIC2, U5-200KD NP_054733 2 1,0
ATP5D "ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit" NP_001678 2 13,7
C17orf27 "chromosome 17 open reading frame 27" KIAA1554 ipi|IPI00828098 2 0,7
C21orf70 "chromosome 21 open reading frame 70" PRED56 NP_478070 2 11,7
CAD "carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase" NP_004332 2 1,2
COPB2 "coatomer protein complex, subunit beta 2 (beta prime)" beta'-COP NP_004757 2 2,1
COPS5 "COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis)" CSN5, JAB1, SGN5, MOV-34, MGC3149 NP_006828 2 7,2
CSNK2A1 "casein kinase 2, alpha 1 polypeptide" CKII, CK2A1, CKII alpha NP_808227 2 4,6
CSNK2A1P "casein kinase 2, alpha 1 polypeptide pseudogene" ipi|IPI00784195 2 4,6
CSPG6 "chondroitin sulfate proteoglycan 6 (bamacan)" BAM, BMH, HCAP, SMC3, SMC3L1 NP_005436 2 2,3
DAP3 "death associated protein 3" DAP-3, MRPS29, MRP-S29, bMRP-10, DKFZp686G12159 NP_387506 2 6,0
DHX15 "DEAH (Asp-Glu-Ala-His) box polypeptide 15" DBP1, HRH2, DDX15, PRP43, PrPp43p NP_001349 2 3,1
DHX9 "DEAH (Asp-Glu-Ala-His) box polypeptide 9" LKP, RHA, DDX9, NDHII, NDH II ipi|IPI00742905 2 1,8
DLST "dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)" DLTS NP_001924 2 5,3
DLSTP "dihydrolipoamide S-succinyltransferase pseudogene (E2 component of 2-oxo-glutarate complex)" ipi|IPI00033034 2 5,3
DPYSL2 "dihydropyrimidinase-like 2" DRP2, CRMP2, DRP-2, DHPRP2 NP_001377 2 3,5
EIF2S1 "eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa" EIF2, EIF-2, EIF2A, EIF-2A, EIF-2alpha NP_004085 2 7,0
H1FX "H1 histone family, member X" H1X, MGC8350, MGC15959 NP_006017 2 11,7
H2AFX "H2A histone family, member X" H2AX, H2A.X, H2A/X NP_002096 2 11,2
H3F3A "H3 histone, family 3A" H3F3, H3.3A, MGC87782, MGC87783 NP_002098 2 11,0
H3F3B "H3 histone, family 3B (H3.3B)" H3.3B NP_005315 2 11,0
HADH2 "hydroxyacyl-Coenzyme A dehydrogenase, type II" ABAD, ERAB, MHBD, HSD17B10, 17b-HSD10 NP_004484 2 11,1
hCG_1641229 ipi|IPI00788270 2 7,5
hCG_1749005 "similar to H3 histone, family 3B" LOC347376 ipi|IPI00232705 2 10,6
HDAC1 "histone deacetylase 1" HD1, RPD3, GON-10, RPD3L1, DKFZp686H12203 NP_004955 2 6,4
HIST1H2AA "histone 1, H2aa" H2AFR, bA317E16.2 NP_734466 2 12,2
HIST1H3A "histone 1, H3a" H3/A, H3FA NP_003520 2 11,0
HIST1H3B "histone 1, H3b" H3/l, H3FL NP_003528 2 11,0
HIST1H3C "histone 1, H3c" H3.1, H3/c, H3FC NP_003522 2 11,0
HIST1H3D "histone 1, H3d" H3/b, H3FB NP_003521 2 11,0
HIST1H3E "histone 1, H3e" H3.1, H3/d, H3FD NP_003523 2 11,0
HIST1H3F "histone 1, H3f" H3/i, H3FI NP_066298 2 11,0
HIST1H3G "histone 1, H3g" H3/h, H3FH NP_003525 2 11,0
HIST1H3H "histone 1, H3h" H3/k, H3FK, H3F1K NP_003527 2 11,0
HIST1H3I "histone 1, H3i" H3.f, H3/f, H3FF NP_003524 2 11,0
HIST1H3J "histone 1, H3j" H3/j, H3FJ NP_003526 2 11,0
HIST2H3A "histone 2, H3a" ipi|IPI00171611 2 11,0
HIST2H3C "histone 2, H3c" H3, H3.2, H3/M, H3F2, H3FM, MGC9629 ipi|IPI00171611 2 11,0
HIST2H3D ipi|IPI00719351 2 8,3
HIST2H3PS2 "similar to histone H2B histone family" LOC440686 ipi|IPI00455457 2 11,0
HIST3H3 "histone 3, H3" H3t, H3.4, H3/g, H3FT NP_003484 2 11,0
HNRPCL1 "heterogeneous nuclear ribonucleoprotein C-like 1" RP5-845O24.4 ipi|IPI00027569 2 7,5
HNRPM "heterogeneous nuclear ribonucleoprotein M" HTGR1, NAGR1, HNRNPM, HNRPM4, HNRNPM4, DKFZp547H118 NP_005959 2 2,9
HRMT1L4 "HMT1 hnRNP methyltransferase-like 4 (S. cerevisiae)" HRMT1L3 NP_062828 2 3,0
IFITM1 "interferon induced transmembrane protein 1 (9-27)" 9-27, CD225, IFI17, LEU13 NP_003632 2 13,6
IFITM2 "interferon induced transmembrane protein 2 (1-8D)" 1-8D NP_006426 2 12,9
IFITM3 "interferon induced transmembrane protein 3 (1-8U)" 1-8U NP_066362 2 12,8
KCTD1 "potassium channel tetramerisation domain containing 1" C18orf5 NP_945342 2 8,2
LOC387753 "similar to 60S ribosomal protein L21" LOC387753 ipi|IPI00398915 2 16,3
LOC388532 "similar to 60S ribosomal protein L21" LOC388532 ipi|IPI00397713 2 18,4
LOC390876 "similar to ribosomal protein L35" LOC390876 ipi|IPI00787131 2 16,9
LOC402057 "similar to 40S ribosomal protein S17" LOC402057 ipi|IPI00414603 2 14,8
LOC440093 "similar to H3 histone, family 3B" LOC440093 ipi|IPI00419884 2 11,1
LOC440563 "similar to Heterogeneous nuclear ribonucleoprotein C-like dJ845O24.4 (hnRNP core protein C-like)" LOC440563 ipi|IPI00455415 2 8,8
LOC440587 "similar to 60S ribosomal protein L6 (TAX-responsive enhancer element binding protein 107) (TAXREB107) (Neoplasm-related protein C140)" LOC440587 ipi|IPI00455427 2 4,5
LOC440737 "similar to 60S ribosomal protein L35" LOC440737 ipi|IPI00455482 2 17,9
LOC644914 ipi|IPI00413826 2 11,0
LOC649330 ipi|IPI00735540 2 7,5
LOC652147 ipi|IPI00740142 2 1,4
LOC653658 ipi|IPI00739952 2 15,0
LOC653737 ipi|IPI00478812 2 16,3
LOC728501 ipi|IPI00788010 2 16,3
LOC728953 ipi|IPI00787105 2 13,7
LOC729362 ipi|IPI00220344 2 20,8
LOC729402 ipi|IPI00247583 2 16,3
LOC729535 ipi|IPI00788063 2 14,9
LOC730004 ipi|IPI00787417 2 33,3
LOC730700 ipi|IPI00788010 2 16,3
LOC730740 ipi|IPI00413826 2 11,0
LOC731499 ipi|IPI00788063 2 14,9
LOC731567 ipi|IPI00247583 2 16,3
LOC731572 ipi|IPI00787105 2 13,7
LOC731640 ipi|IPI00398915 2 16,3
LOC732066 ipi|IPI00787417 2 33,3
LSM4 "LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae)" YER112W NP_036453 2 11,5
MAD2L1 "MAD2 mitotic arrest deficient-like 1 (yeast)" MAD2, HSMAD2 NP_002349 2 8,8
MIF "macrophage migration inhibitory factor (glycosylation-inhibiting factor)" GIF, GLIF, MMIF NP_002406 2 17,4
MRPL11 "mitochondrial ribosomal protein L11" L11mt, CGI-113 NP_733934 2 13,9
MYL6B "myosin light chain 1 slow a" MLC1SA NP_002466 2 11,5
NCKAP1 "NCK-associated protein 1" HEM2, NAP1, NAP125, MGC8981, KIAA0587 NP_995314 2 2,4
NP "nucleoside phosphorylase" PNP, PRO1837 NP_000261 2 6,9
NSF "N-ethylmaleimide-sensitive factor" SKD2 NP_006169 2 3,0
PDAP1 "PDGFA associated protein 1" PAP, PAP1, HASPP28 NP_055706 2 16,0
PDCD4 "programmed cell death 4 (neoplastic transformation inhibitor)" H731, MGC33046, MGC33047 NP_055271 2 4,7
PDHA2 "pyruvate dehydrogenase (lipoamide) alpha 2" PDHAL NP_005381 2 5,2
PRDX6 "peroxiredoxin 6" PRX, p29, AOP2, 1-Cys, NSGPx, aiPLA2, KIAA0106, MGC46173 NP_004896 2 8,5
PSMA2 "proteasome (prosome, macropain) subunit, alpha type, 2" MU, HC3, PSC2, PMSA2 NP_002778 2 12,0
PSME2 "proteasome (prosome, macropain) activator subunit 2 (PA28 beta)" PA28B, REGbeta, PA28beta NP_002809 2 8,8
PSPC1 "paraspeckle component 1" PSP1, FLJ10955, DKFZp566B1447 ipi|IPI00103525 2 4,4
RBMX "RNA binding motif protein, X-linked" RNMX, HNRPG, RBMXP1, RBMXRT NP_002130 2 6,9
RBMXL1 "RNA binding motif protein, X-linked-like 1" KAT3 NP_062556 2 6,9
RETN "resistin" ADSF, RSTN, XCP1, FIZZ3, RETN1 NP_065148 2 24,1
RFC2 "replication factor C (activator 1) 2, 40kDa" A1, RFC40, MGC3665 NP_852136 2 8,5
RFC5 "replication factor C (activator 1) 5, 36.5kDa" RFC36, MGC1155 NP_031396 2 6,8
RPL21 "ribosomal protein L21" L21, FLJ27458, MGC71252 NP_000973 2 16,3
RPL22 "ribosomal protein L22" EAP, HBP15, HBP15/L22 NP_000974 2 18,8
RPL28 "ribosomal protein L28" NP_000982 2 12,4
RPL36 "ribosomal protein L36" DKFZP566B023 NP_056229 2 19,0
RPL36A "ribosomal protein L36a" L44L, MIG6, RPL44, MGC72020 NP_066357 2 20,8
RPL36AL "ribosomal protein L36a-like" RPL36A NP_000992 2 20,8
RPS24 "ribosomal protein S24" DKFZp686N1586 NP_001017 2 20,3
RRM2 "ribonucleotide reductase M2 polypeptide" R2, RR2M NP_001025 2 7,2
SEC23A "Sec23 homolog A (S. cerevisiae)" MGC26267 NP_006355 2 3,4
SEC23B "Sec23 homolog B (S. cerevisiae)" NP_116780 2 3,4
SEPT11 "septin 11" NP_060713 2 4,7
SERPINF1 "serine (or cysteine) proteinase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1" PEDF, EPC-1 NP_002606 2 5,5
SF3B14 "splicing factor 3B, 14 kDa subunit" SF3B14, P14, Ht006, SAP14, CGI-110, HSPC175, SF3B14a NP_057131 2 20,8
SFRS3 "splicing factor, arginine/serine-rich 3" SRp20 NP_003008 2 14,0
SNRPD3 "small nuclear ribonucleoprotein D3 polypeptide 18kDa" SMD3 NP_004166 2 15,1
SNRPE "small nuclear ribonucleoprotein polypeptide E" SME NP_003085 2 25,0
SNRPEL1 "small nuclear ribonucleoprotein polypeptide E-like 1" bA390F4.4 ipi|IPI00068430 2 25,0
SNRPF "small nuclear ribonucleoprotein polypeptide F" SMF NP_003086 2 24,4
SRP54 "signal recognition particle 54kDa" NP_003127 2 4,8
STRBP "spermatid perinuclear RNA binding protein" SPNR, MGC3405, FLJ11307, FLJ14223, FLJ14984, MGC21529, DKFZp434N214 NP_060857 2 3,0
TALDO1 "transaldolase 1" TAL, TALH, TAL-H, TALDOR NP_006746 2 7,1
USP39 "ubiquitin specific protease 39" SAD1, CGI-21, HSPC332, MGC75069 NP_006581 2 4,8
KIAA1618 "KIAA1618" NP_066005 1 1,0
PRDX5 "peroxiredoxin 5" PLP, ACR1, B166, PRXV, PMP20, PRDX6, SBBI10, AOEB166 NP_857635 1 8,8
RNPC2 "RNA-binding region (RNP1, RRM) containing 2" HCC1, CAPER, CC1.3, CC1.4, DKFZp781C0423 ipi|IPI00746554 1 4,8
SFRS7 "splicing factor, arginine/serine-rich 7, 35kDa" 9G8, HSSG1 ipi|IPI00332419 1 8,8
